Vireo Growth VREOF
OTC VREOF
$10.97 -0.01 (-0.09%)
At close: Aug 19, 2026 · 3:35 PM UTC

Vireo Growth (VREOF) Cash from Financing Activities (2020 - 2026)

Vireo Growth (VREOF) posted Cash from Financing Activities of -$4.6 million for Q1 2026, down 7.52% sequentially from -$4.3 million in Q4 2025, and down 411.11% YoY from $1.5 million in Q1 2025.

Vireo Growth (VREOF) Cash from Financing Activities (2020 - 2026) Analysis & Trends

Vireo Growth has reported Cash from Financing Activities for 7 years, with the latest figure at -$4.6 million in Q1 2026.

  • Quarterly Cash from Financing Activities fell 411.11% year-over-year to -$4.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.7 million (down 84.38% YoY) and the FY2025 annual result came in at $18.4 million, down 80.41% from the prior year.
  • Cash from Financing Activities retreated to -$4.6 million in Q1 2026 per VREOF's latest filing, from -$4.3 million in the prior quarter.
  • Over five years, Cash from Financing Activities peaked at $93.4 million in Q4 2024 and troughed at -$9.3 million in Q2 2025.
  • A 5-year average of $8.0 million and a median of $821721.0 in 2023 frame the typical range for Cash from Financing Activities.
  • The widest YoY moves for Cash from Financing Activities: up 45862.26% in 2025, down 609.87% in 2025.
  • Over 5 years, Cash from Financing Activities stood at $245839.0 in 2022, then jumped by 1242.04% to $3.3 million in 2023, then surged by 2730.21% to $93.4 million in 2024, then plunged by 104.58% to -$4.3 million in 2025, then declined by 7.52% to -$4.6 million in 2026.
  • According to Business Quant data, Cash from Financing Activities over the past three periods registered -$4.6 million, -$4.3 million, and $32.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Haleon 43.76 Bn 42.79 Bn - -
2 Teva Pharmaceutical Industries 43.38 Bn 39.73 Bn 2.15 Bn -1.00 Mn
3 Zoetis 31.61 Bn 29.93 Bn 1.05 Bn -813.00 Mn
4 Takeda Pharmaceutical 28.64 Bn 22.84 Bn 5.10 Bn -1.13 Bn
5 United Therapeutics 22.20 Bn 19.54 Bn 683.80 Mn 122.40 Mn
6 Viatris 18.82 Bn 17.93 Bn 1.46 Bn -1.24 Bn
7 Neurocrine Biosciences 15.67 Bn 15.28 Bn 935.80 Mn 63.40 Mn
8 Elanco Animal Health 12.11 Bn 11.58 Bn 798.00 Mn -74.00 Mn
9 Dr Reddys Laboratories 10.10 Bn 9.94 Bn - -
10 Vireo Growth 492.80 Mn 350.50 Mn 95.30 Mn 52.20 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -4.60 Mn
Mar 31, 2026 -4.60 Mn
Dec 31, 2025 -4.28 Mn
Dec 31, 2025 -4.28 Mn
Sep 30, 2025 32.90 Mn
Sep 30, 2025 32.90 Mn
Jun 30, 2025 -9.30 Mn
Jun 30, 2025 -9.30 Mn
Mar 31, 2025 -900,000.00
Mar 31, 2025 -900,000.00
Dec 31, 2024 93.38 Mn
Dec 31, 2024 93.38 Mn
Sep 30, 2024 -71,892.00
Sep 30, 2024 -71,892.00
Jun 30, 2024 1.82 Mn
Jun 30, 2024 1.82 Mn
Mar 31, 2024 -1.12 Mn
Mar 31, 2024 -1.12 Mn
Dec 31, 2023 3.30 Mn
Dec 31, 2023 3.30 Mn